within Pharmacolibrary.Drugs.ATC.J;

model J05AR13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.25,
    adminDuration  = 600,
    adminMass      = 0.6,
    adminCount     = 1,
    Vd             = 0.111,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>The fixed-dose combination of lamivudine, abacavir, and dolutegravir is an oral antiretroviral medication used for the treatment of HIV-1 infection in adults and adolescents. It is currently approved and widely used as a complete regimen in HIV management. Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTIs), while dolutegravir is an integrase strand transfer inhibitor (INSTI).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after oral administration of the fixed-dose combination (Triumeq).</p><h4>References</h4><ol><li><p>Roskam-Kwint, M, et al., &amp; Burger, D (2018). Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure. <i>The Journal of antimicrobial chemotherapy</i> 73(9) 2430â€“2434. DOI:<a href=&quot;https://doi.org/10.1093/jac/dky191&quot;>10.1093/jac/dky191</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29796595/&quot;>https://pubmed.ncbi.nlm.nih.gov/29796595</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AR13;
